Almotriptan in the treatment of migraine

Giorgio Sandrini, Armando Perrotta, Natalia L Arce Leal, Simona Buscone, Giuseppe NappiUniversity Centre for Adaptive Disorders and Headache, IRCCS &ldquo;C. Mondino Institute of Neurology&rdquo; Foundation, University of Pavia, Pavia, ItalyAbstract: Almotriptan is an orally administ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giorgio Sandrini, Armando Perrotta, Natalia L Arce Leal, Simona Buscone, Giuseppe Nappi
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/7c6e1ce8f3824ca3bcd6dc5e5680b199
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7c6e1ce8f3824ca3bcd6dc5e5680b199
record_format	dspace
spelling	oai:doaj.org-article:7c6e1ce8f3824ca3bcd6dc5e5680b1992021-12-02T01:04:53ZAlmotriptan in the treatment of migraine1176-63281178-2021https://doaj.org/article/7c6e1ce8f3824ca3bcd6dc5e5680b1992007-01-01T00:00:00Zhttp://www.dovepress.com/almotriptan-in-the-treatment-of-migraine-a958https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Giorgio Sandrini, Armando Perrotta, Natalia L Arce Leal, Simona Buscone, Giuseppe NappiUniversity Centre for Adaptive Disorders and Headache, IRCCS &ldquo;C. Mondino Institute of Neurology&rdquo; Foundation, University of Pavia, Pavia, ItalyAbstract: Almotriptan is an orally administered, highly selective serotonin 5-HT(1B/1D) receptor agonist that is effective in the acute treatment of moderate to severe migraine attacks. Since its introduction on to the market in 2001, several studies involving a large number of migraine patients have confirmed its efficacy and tolerability profile. Almotriptan, was found to be among the best-responding triptans in terms of pain relief and pain-free rate at 2 h. It has been reported that almotriptan has the best sustained pain-free (SPF) rate and the lowest adverse events (AEs) rate of all the triptans. When these clinical characteristics were combined to form the composite endpoint SPF and no AEs (SNAE), almotriptan emerged as the triptan with the best efficacy and tolerability profile. It also showed a good efficacy profile during the early treatment (within 1 h of onset) of migraine attacks characterized by moderate pain intensity. On the basis of these findings, almotriptan may be considered a therapeutic option for the acute treatment of migraine attacks.Keywords: almotriptan, triptans, migraine, treatment Giorgio SandriniArmando PerrottaNatalia L Arce LealSimona BusconeGiuseppe NappiDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2007, Iss Issue 6, Pp 799-809 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Giorgio Sandrini Armando Perrotta Natalia L Arce Leal Simona Buscone Giuseppe Nappi Almotriptan in the treatment of migraine
description	Giorgio Sandrini, Armando Perrotta, Natalia L Arce Leal, Simona Buscone, Giuseppe NappiUniversity Centre for Adaptive Disorders and Headache, IRCCS &ldquo;C. Mondino Institute of Neurology&rdquo; Foundation, University of Pavia, Pavia, ItalyAbstract: Almotriptan is an orally administered, highly selective serotonin 5-HT(1B/1D) receptor agonist that is effective in the acute treatment of moderate to severe migraine attacks. Since its introduction on to the market in 2001, several studies involving a large number of migraine patients have confirmed its efficacy and tolerability profile. Almotriptan, was found to be among the best-responding triptans in terms of pain relief and pain-free rate at 2 h. It has been reported that almotriptan has the best sustained pain-free (SPF) rate and the lowest adverse events (AEs) rate of all the triptans. When these clinical characteristics were combined to form the composite endpoint SPF and no AEs (SNAE), almotriptan emerged as the triptan with the best efficacy and tolerability profile. It also showed a good efficacy profile during the early treatment (within 1 h of onset) of migraine attacks characterized by moderate pain intensity. On the basis of these findings, almotriptan may be considered a therapeutic option for the acute treatment of migraine attacks.Keywords: almotriptan, triptans, migraine, treatment
format	article
author	Giorgio Sandrini Armando Perrotta Natalia L Arce Leal Simona Buscone Giuseppe Nappi
author_facet	Giorgio Sandrini Armando Perrotta Natalia L Arce Leal Simona Buscone Giuseppe Nappi
author_sort	Giorgio Sandrini
title	Almotriptan in the treatment of migraine
title_short	Almotriptan in the treatment of migraine
title_full	Almotriptan in the treatment of migraine
title_fullStr	Almotriptan in the treatment of migraine
title_full_unstemmed	Almotriptan in the treatment of migraine
title_sort	almotriptan in the treatment of migraine
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/7c6e1ce8f3824ca3bcd6dc5e5680b199
work_keys_str_mv	AT giorgiosandrini almotriptaninthetreatmentofmigraine AT armandoperrotta almotriptaninthetreatmentofmigraine AT natalialarceleal almotriptaninthetreatmentofmigraine AT simonabuscone almotriptaninthetreatmentofmigraine AT giuseppenappi almotriptaninthetreatmentofmigraine
_version_	1718403324827402240

Almotriptan in the treatment of migraine

Ejemplares similares